Removing EPO signalling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

The Risk Estimation of Tumor REcurrence After Transplant score accurately predicted hepatocellular carcinoma recurrence after liver transplantation.

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ-PKAc fusion oncoprotein. However, the underlying mechanism of DNAJ-PKAc’s ...

Multi-modal data integration of single-nuclei RNA and ATAC sequencing with spatial transcriptomics, provides new molecular insights into gene regulatory networks driving cell state transitions in ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

Two international academic journals have found that it is effective to apply classical treatments to patients with advanced ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

A protein identified nearly 40 years ago for its ability to stimulate the production of red blood cells plays a surprising, ...

Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...

Scientists could reshape cancer treatment by helping powerful drugs work better in the body by exploiting a surface protein called CD36 that helps pull substances into cells. This dramatically ...